Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

March 01, 2010 06:25 ET

Global Health Selects Sites for the European Clinical Trials of X-Excite, Its Male Sexual Enhancement Drug

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 1, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) is pleased to announce that its designated CRO, Clinical Investigations Ltd. of United Kingdom has selected Sofia, Bulgaria as the site for its clinical trials, and Amsterdam, the Netherlands for its analytical work. The trial is a Biocompatibility study of the X-Excite, the Company's male sexual enhancement drug, in a comparison study with the current formulation of sildenafil citrate (Viagra®). This study is an open label, randomized, dose escalating and primarily is focused on the drug's pharmacokinetics (blood concentration), biocompatibility (time scale), and efficacy (potency). The trial requires approval of the European Regulatory bodies (EMEA) and must adhere to all rules and regulations of drug approval within the EU Communities of countries.

"The data from these trials will cement the basis for a multinational clinical trials including United States under the FDA guideline, said Dr. Hassan Salari, Global Health President and CEO."

About X-Excite

X-Excite is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. Life style products, such as Viagra™, Cialis™ and Levitra™, etc are highly lucrative, (nearly $5 billion) products for pharmaceutical companies. This lucrative market will continue to grow for the foreseeable future. The arrival of our new drug (X-Excite) with its fewer side effects and the rapid mode of action meets and will exceed the markets needs.

About Global Health Ventures

The Company is a specialty pharma focused on the life style products. The Company is developing a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy.

Notice Regarding Forward Looking Statements

This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products... Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information